Mon, 23 Apr 2018 13:22:04: FDA still not happy with Kamada inhaled AAT drug

Mon, 23 Apr 2018 12:45:47: Synthetic Biologics loses breakthrough status after FDA discovers death imbalance in trial data

Mon, 23 Apr 2018 12:38:32: Targeting heart disease by focusing on a protein that dilates blood vessels

Mon, 23 Apr 2018 12:28:14: After Kerrisdale predictions of failure, Prothena dumps AL amyloidosis drug

Mon, 23 Apr 2018 12:05:43: Sanofi diabetes research chief takes CSO post at Grünenthal

Fri, 20 Apr 2018 15:49:52: A compound from immune cells could treat psoriasis, other autoimmune diseases

Fri, 20 Apr 2018 15:30:00: Gene editing shows promise in combating HIV reservoirs

Fri, 20 Apr 2018 13:59:47: UCB offers $370M for Proximagen’s epilepsy spray, with NDA to follow

Fri, 20 Apr 2018 12:28:00: Biogen pays Ionis $1B to form discovery-stage pact

Fri, 20 Apr 2018 09:18:30: FDA ‘conflicted’ on Lilly and Incyte’s refiled baricitinib

Fri, 20 Apr 2018 09:06:42: MorphoSys supersizes IPO, bagging $208M for cancer R&D

Thu, 19 Apr 2018 21:02:34: After questioning Lilly/Incyte's baricitinib, FDA director jumps ship to AstraZeneca

Thu, 19 Apr 2018 15:03:24: Grail to seek an additional $1B in funding before Hong Kong IPO, report says

Thu, 19 Apr 2018 12:53:03: CNS Pharma turns to crowdfunding to advance glioblastoma drug

Thu, 19 Apr 2018 12:34:23: Tmunity dials series A round up to $135M to fuel progress of T-cell immunotherapy pipeline

Thu, 19 Apr 2018 10:41:29: Novartis lures John Tsai from Amgen to fill CMO seat

Thu, 19 Apr 2018 09:21:24: Novartis’ Jay Bradner bemoans 'redundant investment in the biotech sector' for some cancer R&D

Wed, 18 Apr 2018 20:34:10: 'Cell-free' CRISPR could improve cancer diagnostics, unravel how gene editing works

Wed, 18 Apr 2018 14:20:32: On the hunt for R&D deals, GlaxoSmithKline raids Roche’s executive cupboard again

Wed, 18 Apr 2018 13:34:27: Gottlieb’s pitch: Give the FDA more money and we’ll make drug development more efficient

Wed, 18 Apr 2018 13:00:10: Grid Therapeutics raises $5M for complement-activating I-O drug

Wed, 18 Apr 2018 12:37:45: Oncolytics Biotech’s CMO departs on cusp of phase 3 trial

Tue, 17 Apr 2018 12:54:18: Johnson & Johnson scraps phase 3 antibiotic program acquired in $30B Actelion takeover

Tue, 17 Apr 2018 12:50:57: Basilea slots ArQule FGF drug into its cancer portfolio

Tue, 17 Apr 2018 12:09:41: J&J buys into Bristol-Myers cardiovascular disease program